摘要
目的：探讨美洛培南治疗早产儿产超广谱β-内酰胺酶（ESBLs）菌感染的临床疗效及安全性。方法：新生儿重症监护病房（NICU）早产儿产ESBLs菌感染11例，给予美洛培南治疗，均静脉给药，剂量为每次20mg／kg，每8h一次。用药期间密切观察患儿生命体征，监测血、尿常规和肝肾功能、凝血功能。结果：11例全部痊愈，用药时间7-10d，平均8d。用药前后监测血生化、肝肾功能、凝血功能均未见异常，未见其它不良反应。结论：美洛培南适合NICU用于治疗早产儿产ESBLs菌感染。
Objective： To investigate the clinic effect and safety of meropenem on infections of extend-spectrum beta-lactamas-producing （ESBLs） bacteria in premature infants. Methods： Eleven premature infants with infection of ESBLs-preducing bacteria in neonatal intensive care unit （NICU） were involved in this study and treated with venous injection of meropenem with a dose of 60 mg/（kg· d）. At the same time, some concerned targets were tested. Results： At the end of the course treated with meropenem, 11 cases were all healed. No side effect was observed. Conclusions： Meropenem is suitable for treating premature infants with infection of ESBLs-producing bacteria in NICU.
出处
《儿科药学杂志》
CAS
2007年第6期50-51,共2页
Journal of Pediatric Pharmacy
作者简介
廖积仁（1965．1-），女，大学本科，副主任医师，主要从事新生儿疾病研究，E-mail：liaojiren8888@sina．com。
